Thai Lee, of Austin, remains at the top of the list in Texas. Photo courtesy of SHI

Of the country's 100 most successful female entrepreneurs, 12 call Texas home, according to Forbes and its 2023 list of America's Richest Self-Made Women, released June 1.

"Bolstered in part by a rebound in the stock market, [the richest 100 female entrepreneurs] are cumulatively worth a record $124 billion, up nearly 12 percent from a year ago," says Forbes.

To make the Forbes list, women had to garner wealth on their own, rather than by inheriting or winning it. Texas' wealthiest women have made their fortunes in fields ranging from home health care, insurance, and aviation logistics to jewelry design, dating apps, and running the show at SpaceX. Austin is home to the largest concentration of these self-made Texans with eight Austinites making the list.

With an estimated net worth at $4.8 billion, Thai Lee, of Austin, remains at the top of the list in Texas, and ranks No. 5 nationally.

She falls behind only No. 1 Diane Hendricks of Wisconsin (co-founder of ABC Supply, $15 billion net worth); No. 2 Judy Love of Oklahoma (chairman and CEO, Love's Travel Stops And Country Stores, $10.2 billion); No. 3 Judy Faulkner of Wisconsin (founder and CEO, Epic Systems, $7.4 billion); and No. 4 Lynda Resnick of California (co-founder and co-owner of Wonderful Company, $5.3 billion) among America's richest self-made women.

For some additional perspective, Oprah Winfrey lands at No. 13 on the list for 2023. The TV titan (and most famous woman on the planet) has an estimated net worth of $2.5 billion, Forbes says.

Austin's Lee, a native of Bangkok who holds an MBA from Harvard University, is founder, president, and CEO of SHI International Corp., a provider of IT products and services with a projected revenue of $14 billion in 2023. Fun fact: "Lee majored in both biology and economics," Forbes says, "in part because her English was less than perfect and she wanted to avoid writing and speaking in class."

The other seven Austin women on the list are:

  • Lisa Su, No. 34, Austin. Forbes pegs Su’s net worth at $740 million, tying her with April Anthony of Dallas. The native of Taiwan is president and CEO of Santa Clara, California-based semiconductor company Advanced Micro Devices.
  • Kendra Scott, No. 47, of Austin.Forbes says she has amassed a net worth of $550 million as founder of Kendra Scott LLC, which designs and sells jewelry in more than 100 stores (and is worth $360 million). The celebrity entrepreneur is also a judge on TV's Shark Tank.
  • Whitney Wolfe Herd, No. 52, of Austin. She is worth an estimated $510 million. Herd is co-founder and CEO of Bumble Inc., which operates two online dating apps: Bumble and Badoo. She owns a 17% stake in Bumble and became the youngest self-made woman billionaire after it went public in February 2021.
  • Paige Mycoskie, No. 73, of Austin. She is worth an estimated $380 million. Mycoskie created founded her 1970s-inspired California lifestyle brand, Aviator Nation, which took off during the pandemic and now has 16 retail locations across the U.S. If the name sounds familiar, that's because she's the sister of TOMS founder Blake Mycoskie, with whom she competed on TV's The Amazing Race.
  • Imam Abuzeid, No. 77, of Austin. Her net worth is estimated at $350 million. Abuzeid is the co-founder and CEO of Incredible Health, which she started in 2017 to help alleviate America's nursing shortage. Forbes describes it as "a souped-up version of LinkedIn for nurses." Abuzeid is one of only a handful of Black female founders to run a company valued at more than $1 billion, Forbes notes.
  • Julia Cheek, No. 92, of Austin. Her net worth is estimated at $260 million. Cheek founded at-home testing company Everly Health in 2015 "out of frustration at having to pay thousands for lab testing to diagnose issues related to vitamin imbalance," Forbes says. It got a Shark Tank deal with Lori Greiner and is now worth roughly $1.8 billion.
  • Belinda Johnson, No. 96, of Austin. She is worth an estimated $250 million. Johnson was Airbnb's first chief operating officer and led many of its legal disputes. She stepped down from that role in March 2020, Forbes says, and left the company's board in June 2023.

The remaining Texas women on the list include:

  • Gwynne Shotwell, No. 27, of Jonesboro (Coryell-Hamilton counties). Her net worth is estimated at $860 million. Shotwell is president and COO of Elon Musk's SpaceX. She manages the operations of the commercial space exploration company and owns an estimated stake of 1 percent, Forbes says.
  • Robyn Jones, No. 29, of Fort Worth. Her net worth is estimated at $830 million. Jones is founder of Westlake-based Goosehead Insurance Agency LLC. She started the property and casualty insurance agency in 2003 after being frustrated with her truck-driver husband's "road warrior lifestyle," Forbes says. He joined her in 2004 and they took the company public in 2018. It has nearly 1,000 franchised offices.
  • April Anthony, No. 34, of Dallas. Forbes puts her net worth at $740 million. She founded the Dallas-based home health and hospice division of Encompass Health Corp and sold it for $750 million to HealthSouth. In 2022, she was named CEO of VitalCaring, a home health and hospice care firm.
  • Kathleen Hildreth, No. 44, of Aubrey. Her net worth is estimated at $590 million. Hildreth is co-founder of M1 Support Services LP, an aviation logistics company based in Denton. A service-disabled Army veteran, she graduated from West Point in 1983 and was deployed all around the world as a helicopter pilot.
------

This article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston digital health platform Koda lands strategic investment

money moves

Houston-based advance care planning platform Koda Health has added another investor to the lineup.

The company secured a strategic investment for an undisclosed amount from UPMC Enterprises, the commercialization arm of the University of Pittsburgh Medical Center. The funding is part of Koda's oversubscribed series A funding round that closed in October, according to a release.

"UPMC Enterprises’ investment is a meaningful signal, not just to Koda, but to the broader market," Dr. Desh Mohan, chief medical officer and co-founder of Koda Health, said in the news release. "It validates that health systems are ready to invest in infrastructure that makes advance care planning work the way it should: proactively, at scale, and with the human support that these conversations require. Having UPMC Enterprises as a strategic investor puts us in a unique position to prove what's possible."

Koda has raised $14 million to date, according to a representative from the company. Its series A round was led by Evidenced, with participation from Mudita Venture Partners, Techstars and the Texas Medical Center last year. At the time, the company said the funding would allow it to scale operations and expand engineering, clinical strategy and customer success. The company described the round as a "pivotal moment," as it had secured investments from influential leaders in the healthcare and venture capital space.

Koda Health, which was born out of the TMC's Biodesign Fellowship in 2020, saw major growth last year, as well, and now supports more than 1 million patients nationwide through partnerships with Cigna Healthcare, Privia Health, Guidehealth, Sentara, UPMC and Memorial Hermann Health System.

The company integrated its end-of-life care planning platform with Dallas-based Guidehealth in April 2025 and with Epic Systems in July 2025. It also won the 2025 Houston Innovation Award in the Health Tech Business category. Read more here.

New 'living pharmacy' biotech company launches out of Rice venture studio

fighting cancer

Rice University’s biotech venture studio RBL LLC has launched a new “living pharmacy” company, Duracyte, designed to make cancer treatment easier on patients.

Backed by an up to $45 million Advanced Research Projects Agency for Health (ARPA-H) award, Duracyte aims to commercialize implantable biohybrid pharmacy devices that are designed to produce therapeutic proteins inside the human body around the clock, replacing the need for regular injections and infusions for some cancer patients.

The company’s main platform is its Hybrid Advanced Molecular Manufacturing Regulator (HAMMR), a rechargeable, implantable device that can sense biological signals, monitor tumor environments and adjust therapeutic output in real time. HAMMR has wireless communication capabilities, which allow patients and clinicians to remotely monitor results through an app every five minutes and make changes to treatment plans without a hosptial visit. Additionally, the device can generate its own oxygen supply, which is key for the therapeutic cells’ survival.

“Biologic medicines such as monoclonal antibodies, cytokines and metabolic regulators already account for a significant share of modern therapeutics, but the way we deliver them today often requires frequent injections or infusions that can be demanding for patients and lead to inconsistent drug levels,” Daniel Anderson, MIT professor and co-founder of Duracyte, said in a news release. “Our vision is to enable a continuous, stable therapy by producing these medicines directly inside the body, which could improve treatment consistency, reduce side effects and ultimately transform how biologic therapies are delivered across many diseases.”

Duracyte’s first clinical trial is slated to begin by the end of 2026 and will focus on recurrent ovarian cancer. The Phase I study will build upon existing work on encapsulated cytokine pharmacy technology, and the company hopes that within a few years this treatment can reach clinical application.

The development of Duracyte is supported by ARPA-H's Targeted Hybrid Oncotherapeutic Regulation (THOR) project, which supports a multidisciplinary research consortium co-led by Omid Veiseh, a professor of bioengineering at Rice. The consortium also includes others at Rice, The University of Texas MD Anderson Cancer Center, Stanford University, Carnegie Mellon University, Northwestern University and the University of Houston, plus industry collaborators like Chicago-based CellTrans.

“What we are building is the culmination of years of progress in cell engineering, biomaterials and implantable device technology,” Veiseh added in the release. “By combining these advances with real-time sensing and adaptive drug delivery, we are working with the support of RBL to create a true ‘living pharmacy’ that can deliver continuous, precisely controlled biologic therapies and fundamentally change how these treatments reach patients.”

RBL launched in 2024 and is based out of Houston’s Texas Medical Center Helix Park. Duracyte is the third company launched by RBL, including Sentinel BioTherapeutics, a clinical-stage immunotherapy company developing localized cytokine therapies for solid tumors, and SteerBio, a regenerative medicine company targeting lymphedema.

“Duracyte exemplifies the kind of breakthrough that Houston’s ecosystem is built to produce,” Paul Wotton, managing partner of RBL LLC and co-founder of Duracyte, added in the release. “With world-class clinical infrastructure, exceptional engineering talent and initiatives like the Texas Biotech Task Force driving alignment across industry, investment and talent, this region is uniquely positioned to move the most ambitious ideas in medicine from concept to patient, faster than anywhere else.”